David Tutera, Celebrity Wedding & Event Expert Designs, Plans & Officates the Virtual Wedding of the Year

A front-line responder, a hero, surprised by David Tutera, as he sets to bring her Dream Wedding to LIFE

Creating celebrations is NOT a job to me, it’s my passion… I simply love what I do!”

— David Tutera

MALIBU, CA, USA, May 28, 2020 /EINPresswire.com/ — During these challenging and unprecedented times, Leading Wedding & Entertaining Expert, David Tutera is inspired to bring JOY and to shed LIGHT, LOVE and to continue to create special LIFE MOMENTS when we need it most. David will surprise, design and officiate the wedding of one lucky couple ~ Andrea & Ethan ~ making their dream come true. This couple, unfortunately was not able to move forward with their original plans; but David will stop at nothing to bring this special moment to LIFE.

The Mother-of-the-Bride, Wanda Minken, a long-time follower of David, reached out to share details about her daughter, Andrea, a Connecticut Physician Assistant, working 65-80 hours a week in the Intensive Care Unit treating Covid-19 patients. Andrea gets up every morning at 4:30am to prepare for another day in the trenches, not returning home until after 7:30pm. “Every day is a physical and emotional drain, shares Wanda, “but Andrea is a kind and compassionate young woman that treats all of her patients and families with dignity and grace, especially in these most desperate times.” She is known to many as "A Warrior in Scrubs"!

Although her spirit is broken, and she is disappointed that she has had to postpone her wedding, Andrea believes her wedding is trivial compared to what is happening around her. This is where David comes in!

David will surprise the couple LIVE…and continue the process of planning, designing and executing the vision of their dream wedding…LIVE. “Creating celebrations is NOT a job to me, it’s my passion…I simply love what I do!”, says David. From planning to execution to providing all the elements they need, David and his team will work closely with the amazing partners he has brought together, to make sure that this special couple gets the wedding ceremony of their dreams, on the exact date of their original wedding, June 27, 2020.

To bring this Virtual Wedding of the Year to life, David is partnering with PartySlate, a photo-rich platform that inspires people planning events and connects them with the leading event professionals and venues across the country and the world; and a host of other amazing partners including Butterfly Florals, Dogwood Blossom Stationery, Stitch & Tie by Friar Tux and Impressive Creations.

David’s true goal is always to make the bride & groom feel like a guest at their own celebration and to always create an “EXPERIENCE” for all who attend. A dream can become a reality with the expertise of David Tutera and team, whether it’s in person or virtual. A feel good story is what the world needs right now! David Tutera is the perfect person to bring this Celebration and Special Moment to LIFE!

David Tutera, entertaining expert, event designer, motivational speaker, TV personality, fashion designer, lifestyle brand and author, is hailed as an artistic visionary whose ability, uniquely creative talents and passion for designing has made him a tremendous success in the event and lifestyle arena. David's specialty is creating one of a kind celebrations that truly represent the honoree(s). It is through the details in every aspect of an event that an event can be the perfect medium to tell the perfect celebration story.

David's award winning, full-service, domestic and global brand is built from experience, dedication and his natural talent for transforming the ordinary into the extraordinary. David began his career in party planning more than thirty years ago, and today, he continues to create magic and make dreams come true. David measures his success by being a father of two beautiful girls, Cielo and Gracie and loving husband to Joey.

PartySlate is a photo-rich platform that inspires people planning events and connects them with the leading event professionals and venues across the country and the world.

Since its founding in 2015, PartySlate has acquired 10,000 of the world’s top event professionals and venues who have uploaded more than 750,000 beautiful event photos to the website. PartySlate is headquartered in Chicago and has launched in 17 cities.

Lisa Newberry
Dada Media, Inc., dba David Tutera
+1 310-570-7611
email us here
Visit us on social media:

Source: EIN Presswire

Research at MDI Biological Laboratory Explores Novel Pathways of Regeneration and Tumorigenesis

Dustin Updike, Ph.D., of the MDI Biological Laboratory in Bar Harbor, Maine

Dustin Updike's research on germ granules offers another route to repairing damaged tissues and organs in cases where therapeutic options are limited or non-existent.”

— Hermann Haller, M.D, president, MDI Biological Laboratory

BAR HARBOR, MAINE, UNITED STATES, May 28, 2020 /EINPresswire.com/ — Research by scientists at the MDI Biological Laboratory in Bar Harbor, Maine, is opening up new approaches to promoting tissue regeneration in organs damaged by disease or injury.

In recent years, research in regenerative biology has focused on stem cell therapies that reprogram the body’s own cells to replace damaged tissue, which is a complicated process because it involves turning genes in the cell’s nucleus on and off.

A recent paper in the journal Genetics by MDI Biological Laboratory scientist Elisabeth Marnik, Ph.D., a postdoctoral fellow in the laboratory of Dustin Updike, Ph.D., offers insight into an alternate pathway to regeneration: by recreating the properties of germ cells.

Germ cells, which are the precursors to the sperm and egg, are considered immortal because they are the only cells in the body with the potential to create an entirely new organism. The stem cell-like ability of germ cells to turn into any type of cell is called “totipotency.”

“By getting a handle on what makes germ cells totipotent, we can promote regeneration by unlocking the stem cell-like properties of other cell types,” said Updike. “Our research shows that such cells can be reprogrammed by manipulating their cytoplasmic composition and chemistry, which would seem to be safer and easier than changing the DNA within a cell’s nucleus.”

Using the tiny, soil-dwelling nematode worm, C. elegans, as a model, the Updike lab studies organelles called germ granules that reside in the cytoplasm (the contents of the cell outside of the nucleus) of germ cells. These organelles, which are conserved from nematodes to humans, are one of the keys to the remarkable attributes of germ cells, including the ability to differentiate into other types of cells.

In their recent paper entitled “Germline Maintenance Through the Multifaceted Activities of GLH/Vasa in Caenorhabditis elegans P Granules,” Updike and his team describe the “intriguing and elusive” role of “Vasa” proteins within germ granules in determining whether a cell is destined to become a germ cell with totipotent capabilities or a specific type of cell, like those that comprise muscle, nerves or skin.

Because of the role of Vasa proteins in preserving totipotency, an increased understanding of how such proteins work could lead to unprecedented approaches to de-differentiating cell types to promote regeneration; or alternatively, to new methods to turn off totipotency when it is no longer desirable, as in the case of cancer.

“The increase in chronic and degenerative diseases caused by the aging of the population is driving demand for new therapies,” said MDI Biological Laboratory President Hermann Haller, M.D. “Dustin’s research on germ granules offers another route to repairing damaged tissues and organs in cases where therapeutic options are limited or non-existent, as well as an increased understanding of cancer.”

Because of the complexity of the cellular chemistry, research on Vasa and other proteins found in germ granules is often overlooked, but that is rapidly changing — especially among pharmaceutical companies — as more scientists realize the “impact and potential” of such research, not only for regenerative medicine but also for an understanding of tumorigenesis, or cancer development, Updike said.

Recent research has found that some cancers are accompanied by the mis-expression of germ granule proteins, which are normally found only in germ cells. The mis-expression of these germ-granule proteins seems to promote the immortal properties of germ cells, and consequently tumorigenesis, with some germ-granule proteins now serving as prognosis markers for different types of cancer, Updike said.

Updike is a former postdoctoral researcher in the laboratory of Susan Strome, Ph.D., at University of California, Santa Cruz. Strome, who was inducted into the National Academy of Sciences last year, first discovered P granules more than 30 years ago. She credits Updike, who has published several seminal papers on the subject, with “great imagination, determination and excellent technical skill” in the pursuit of his goal of elucidating the function and biochemistry of these tiny organelles.

The lead author of the new study from the Updike laboratory, Elisabeth A. Marnik, Ph.D., will be launching her own laboratory at Husson University in Bangor, Maine, this fall. Other contributors include J. Heath Fuqua, Catherine S. Sharp, Jesse D. Rochester, Emily L. Xu and Sarah E. Holbrook. Their research was conducted at the Kathryn W. Davis Center for Regenerative Biology and Medicine at the MDI Biological Laboratory.

Updike’s research is supported by a grant (R01 GM-113933) from the National Institute of General Medical Sciences (NIGMS), an institute of the National Institutes of Health (NIH). The equipment and cores used for part of the study were supported by NIGMS-NIH Centers of Biomedical Research Excellence and IDeA Networks of Biomedical Research Excellence grants P20 GM-104318 and P20 GM-203423, respectively.

About the MDI Biological Laboratory

We aim to improve human health and healthspan by uncovering basic mechanisms of tissue repair, aging and regeneration, translating our discoveries for the benefit of society and developing the next generation of scientific leaders. For more information, please visit mdibl.org.

Stefanie Matteson
MDI Biological Laboratory
+1 201-787-7427
email us here

Source: EIN Presswire

Impact of COVID-19 on Global Contraceptives Drugs and Devices Market 2020 Trend, Segmentation and Forecast to 2026

New Study Reports "Contraceptives Drugs and Devices Market 2020 Global Market Opportunities, Challenges, Strategies and Forecasts 2026" has been Added.

PUNE, MAHARASHTRA, INDIA, May 29, 2020 /EINPresswire.com/ — Contraceptives Drugs and Devices Market 2020-2026

New Study Reports "Contraceptives Drugs and Devices Market 2020 Global Market Opportunities, Challenges, Strategies and Forecasts 2026" has been Added on WiseGuyReports.

Introduction/Report Summary:

This report provides in depth study of “Contraceptives Drugs and Devices Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Contraceptives Drugs and Devices Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

Contraceptives are birth spacing products that aid in avoiding unwanted/ unplanned pregnancy. There are five widely used contraceptive methods namely barrier method, hormonal method, emergency contraception, intrauterine method, and sterilization. Women can opt for wide range of contraceptive options such as vaginal rings, diaphragms, female condoms, oral pills, and intra-uterine devices (IUD). Selecting the most appropriate method is critical to avoid undesired side effects.

Drivers and Constraints

The fundamental dynamics that are explored in the report hold substantial influence over the Contraceptives Drugs and Devices market. The report further studies on the value, volume trends, and the pricing history of the market. In addition to it, various growth factors, restraints, and opportunities are also analyzed for the market to study the in-depth understanding of the market.

This report also analyzes the impact of Coronavirus COVID-19 on the Contraceptives Drugs and Devices industry.

Key Players

The report has profiled some of the Important players prevalent in the global like – Teva Pharmaceutical Industries Ltd, Church & Dwight Co. Inc, Reckitt Benckiser Plc, Pfizer, Inc, Bayer AG, Mayer Laboratories, Inc, The Female Health Company, Cooper Surgical, Inc, Allergan plc, Cipla Limited, Merck & Co. Inc, and more.

This report covers the sales volume, price, revenue, gross margin, manufacturers, suppliers, distributors, intermediaries, customers, historical growth and future perspectives in the Contraceptives Drugs and Devices.

Request for Free Sample Report of “Contraceptives Drugs and Devices” Market @  https://www.wiseguyreports.com/sample-request/5337844-covid-19-impact-on-contraceptives-drugs-and-devices

Market Segmentation based On Type, Application and Region:

The global Contraceptives Drugs and Devices is analyzed for different segments to arrive at an insightful analysis. Such segmentation has been done based on type, application, and region.

Based on Type, the global Contraceptives Drugs and Devices Market is segmented into Contraceptive Drugs (Oral Contraceptive Pills, Contraceptive Injectables, Topical Contraceptives), Contraceptive Devices (Male Contraceptive Devices, Female Contraceptive Devices) and other

Based on Application, the Contraceptives Drugs and Devices Market is segmented into Female, Male, and Others.

Based on Detailed Regional Analysis, the regional segmentation has been carried out for regions of U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America. The report on WGR includes an in-depth study of the Contraceptives Drugs and Devices in each regional segment mentioned above.

Key Stakeholders 
Contraceptives Drugs and Devices Market Manufacturers 
Contraceptives Drugs and Devices Market Distributors/Traders/Wholesalers 
Contraceptives Drugs and Devices Market Subcomponent Manufacturers 
Industry Association 
Downstream Vendors

If you have any special requirements, please let us know and we will offer you the report as you want.

Complete Report Details@ https://www.wiseguyreports.com/reports/5337844-covid-19-impact-on-contraceptives-drugs-and-devices

Major Key Points from Table of Content:

1.1 Research Scope
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Contraceptives Drugs and Devices Industry
1.7 COVID-19 Impact: Contraceptives Drugs and Devices Market Trends

7 Company Profiles
7.1 Teva Pharmaceutical Industries Ltd
7.1.1 Teva Pharmaceutical Industries Ltd Business Overview
7.1.2 Teva Pharmaceutical Industries Ltd Contraceptives Drugs and Devices Quarterly Production and Revenue, 2020
7.1.3 Teva Pharmaceutical Industries Ltd Contraceptives Drugs and Devices Product Introduction
7.1.4 Teva Pharmaceutical Industries Ltd Response to COVID-19 and Related Developments
7.2 Church & Dwight Co. Inc
7.2.1 Church & Dwight Co. Inc Business Overview
7.2.2 Church & Dwight Co. Inc Contraceptives Drugs and Devices Quarterly Production and Revenue, 2020
7.2.3 Church & Dwight Co. Inc Contraceptives Drugs and Devices Product Introduction
7.2.4 Church & Dwight Co. Inc Response to COVID-19 and Related Developments
7.3 Reckitt Benckiser Plc
7.3.1 Reckitt Benckiser Plc Business Overview
7.3.2 Reckitt Benckiser Plc Contraceptives Drugs and Devices Quarterly Production and Revenue, 2020
7.3.3 Reckitt Benckiser Plc Contraceptives Drugs and Devices Product Introduction
7.3.4 Reckitt Benckiser Plc Response to COVID-19 and Related Developments
7.4 Pfizer, Inc
7.4.1 Pfizer, Inc Business Overview
7.4.2 Pfizer, Inc Contraceptives Drugs and Devices Quarterly Production and Revenue, 2020
7.4.3 Pfizer, Inc Contraceptives Drugs and Devices Product Introduction
7.4.4 Pfizer, Inc Response to COVID-19 and Related Developments

and more

Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.


+1 646-845-9349
email us here

Source: EIN Presswire

Transvaginal Mesh Litigation: A Focused Look at Compensatory Damages Post-MDL

Women with disabling injuries have yet to settle claims against TVM manufacturers because accepting the offer would result in living as a medical indigent.

I have talked to women injured by Ethicon and Boston Scientific… destroyed by pudendal neuralgia, and offered pennies on the dollar by tier settlements that did nothing to prevent medical indigence.”

— Dr. Greg Vigna

SANTA BARBARA, CA, UNITED STATES, May 28, 2020 /EINPresswire.com/ — Within the rubble of the West Virginia Transvaginal Mesh Multidistrict Litigation (MDL) are likely a few hundred or so brave women with disabling injuries who have yet to settle their claims against the manufacturers because accepting the offered compensation under the tier settlements would have punched their ticket to a life-time living as a medical indigent. Many within the rubble have symptoms or diagnoses consistent with neurological injuries caused by the defectively designed products of Bard, American Medical Systems, Ethicon, Coloplast, and Boston Scientific. Many are disabled and alone; some divorced; and most struggling week to week to gather the basic necessities of life.

Dr. Greg Vigna, national pharmaceutical injury attorney, practicing physicians, and Certified Life Care Planner says, “June 21, 2018 was a very important date for the women holding on within the MDL because it signaled the time that seriously injured women could have their cases directly filed in courts outside the MDL and have a clear path to the courthouse without being stuck in the MDL. It signaled the time when serious trial attorneys could step up and litigate these cases.”

Dr. Vigna states, “I have talked to women over the years injured by Ethicon and Boston Scientific, with their deep pockets, destroyed by pudendal neuralgia, and offered pennies on the dollar by tier settlements that did nothing to prevent their medical indigence. The MDL was about erosion and not about neurological injury. Since the MDL closed its doors to new cases, my law firm with co-counsel of experienced pharmaceutical trial attorneys were the first to file a newly injured women diagnosed with pudendal neuralgia in California, and we have since filed dozens of cases for seriously injured women across the country.”

Dr. Vigna adds, “We represent women in the ‘wave’ discovery process of the MDL, women remanded to state courts from the MDL, and women who are subject to a tolling agreement after their case was dismissed without prejudice in the MDL. These women will be marched to the courthouse while we work up their cases for trial.”

Martin Baughman, PLLC from Dallas Texas, a national pharmaceutical injury trial firm, has filed many of these cases. Ben Martin, Esq. states, “The purpose of product liability law is injury reduction and compensation. Looking at the serious injuries of the women I represent, it is obvious that the manufacturers to date haven’t owned up to the harm they have caused.”

Mr. Martin adds, “We are carefully investigating cases to ensure that women who have neurological injuries who are severely harmed are represented.”

Compensatory damages in a product injury lawsuit include past and future losses along with payment for their pain and suffering. Past losses include those from vocational disability and cost of medical care, as well as future monetary losses including the cost of necessary and appropriate care. Vocational loss and future care require evidence—sometimes presented by vocational and economic experts and life care planners.

Ben Martin and Laura Baughman are national pharmaceutical injury attorneys in Dallas, Texas. Dr. Vigna is a California and Washington DC lawyer who focuses on catastrophic injuries caused by transvaginal mesh devices including pudendal neuralgia, obturator neuralgia, ilioinguinal neuralgia, and Complex Regional Pain Syndrome.

For articles, video resources, and information visit the Pudendal Neuralgia Educational Portal (https://pudendalportal.lifecare123.com/) or https://tvm.lifecare123.com/.

Click here for information regarding sling related complications: https://tvm.lifecare123.com/slingebook.html
Click here for a FREE BOOK on Vaginal Mesh Pain: https://vignalawgroup.com/publications/

Greg Vigna, MD, JD
Vigna Law Group
1155 Coast Village Rd., Suite 3, Santa Barbara, CA

Greg Vigna
Greg Vigna, M.D., J.D., PLC
+1 800-761-9206
email us here
Visit us on social media:

Source: EIN Presswire

ShowStoppers® TV features Energous, HyperX, Jabra, MYHIXEL, Xandar Kardian healthtech in broadcast to journalists

ShowStoppers® TV features healthtech from Energous, HyperX, Jabra, MYHIXEL, Xandar Kardian in press conference broadcast to journalists worldwide

AUSTIN, TX, UNITED STATES, May 28, 2020 /EINPresswire.com/ — Today’s online broadcast of ShowStoppers® TV, http://www.showstoppers.com, featured four companies with tools, products and healthtech for wellness – connecting Energous, HyperX, Jabra, MYHIXEL and Xandar Kardian with technology and business journalists around the globe.

Creating the first series of showcase events on the digital screen as a new platform for multiple companies to launch products and services, meet the press, and generate coverage, the ShowStoppers TV broadcast episodes are online editions of the in-person press events that ShowStoppers organizes at CES, IFA, Mobile World Congress, CEATEC, NAB Show and other tradeshows around the world.

Journalists from 31 countries registered in advance to attend the one-hour broadcast, organized as a virtual press conference. Each company presented for ten minutes, with questions moderated by Helena Stone, editor in chief of Geekspin.co, http://www.geekspin.co; entrepreneur, founder and former editor of Chip Chick, which grew to be the top tech site for women; featured on MSNBC, Wired, ABC News, People, Time Magazine, Women's Day and other major news outlets. At the end of the broadcast, each company was provided a private virtual meeting room to continue the conversation with specific questions from journalists.

Energous, http://www.energous.com, showed “its latest WattUp wireless charging technology, as well as its recently announced WattUp PowerHub solution, specifically focusing on wireless charging for health/medical IoT applications such as fitness bands, smartwatches, hearables, smart glasses, medical devices and more,” said Gordon Bell, vice president, marketing.

HyperX, www.hypergaming.com, a division of Kingston Technology Inc., announced new eyewear for parents and children gaming at home, and for parents working from home in front of a computer screen for hours. “The new HyperX eyewear is designed to be comfortable even while wearing a gaming headset. It filters out the blue light that is known to cause fatigue or eyestrain,” said Mark Tekunoff, corporate public relations manager.

“Summer is here, and whether you’re heading outside to run, bike, hike, or to take a walk – Jabra’s Elite Active 75t true wireless earbuds are your perfect outdoor activity companion. The earbuds offer a small and lightweight design for all-day, secure and comfortable wear and have a battery life of 7.5 hours on a single charge – with an extra two charges in the case. You can easily pair the earbuds with your devices to stream your favorite playlists; they’re waterproof and sweat-and-dust-resistant,” said Adam Robertson, director of product marketing at Jabra, www.jabra.com.

“MYHIXEL is a medical innovator presenting a revolutionary male sexual health solution,” said Dominnique Karetsos, https://myhixel.com. “MYHIXEL is the first medically proven gamification Play App + Device that guarantees next-level pleasure, designed specifically to achieve climax control.”

“None of us know when we will have a vaccine for COVID19,” said David Kim, chief financial and strategy officer, Xandar Kardian, http://www.xkcorp.com. “But Xandar Kardian’s vital sign sensor provides continuous, non-contact, autonomous, real-time monitoring of patient conditions and well-being. XK’s proprietary solution helps Long-Term-Care facilities increase staff efficiency, particularly so at a time when staffing shortages are a major concern for healthcare service providers.”

About ShowStoppers TV

ShowStoppers TV premiered 2 Apr. 2020 as a new online broadcast edition of the industry-leading in-person events that ShowStoppers produces around the world.

“We know how challenging it is now to do business, to make a difference,” said Dave Leon, partner, ShowStoppers. “We believe ShowStoppers TV builds on our extensive event production experience to create showcase events on the digital screen that help multiple companies connect with journalists globally in order to launch new products and services that cope with today’s new realities.”

About ShowStoppers

Now in its 25th year, ShowStoppers, http://www.showstoppers.com/, is the global leader in producing press and business events spanning the U.S., Europe and Asia. Each event organizes product launches, sneak previews and demonstrations for selected journalists, bloggers, industry and financial analysts, venture capitalists and business executives. Industry leaders, innovators and startups exhibit to generate news coverage and product reviews, make new connections, promote brand and open new markets.

ShowStoppers produces official press events at CES, CE Week, IFA and NAB; partners with MWC and CEATEC; and produces events during CES and other tradeshows.

To sign up to meet the press at ShowStoppers press events online at ShowStoppers TV and in-person around the world, contact Lauren Merel, mailto:lauren@showstoppers.com, +1 908-692-6068.

Steven Leon
+1 3109368530
email us here

Source: EIN Presswire

AACR Integrates with Code Ocean

This is an example of a Code Ocean compute capsule associated to a article published in Cancer Research in

Code Ocean compute capsule associated to an article published in Cancer Research

American Association for Cancer Research Journals Integrate Code Ocean to Help Improve Research Reproducibility

NEW YORK, NY, UNITED STATES, May 28, 2020 /EINPresswire.com/ — Code Ocean, a computational reproducibility platform, is pleased to announce that the American Association for Cancer Research (AACR), the largest professional organization related to cancer research, will integrate Code Ocean into the AACR journals platform.

Code Ocean enables authors to share fully functional and executable code accompanying their articles and to allow readers to re-run the analysis in the cloud and reproduce the results, bypassing the need to install the software. Authors upload their software code, with either test or actual raw data, to the Code Ocean online software environment. Code Ocean then verifies the code and, once the article is published, allows others to easily run, edit, and reuse the code from any web browser.

“The integration of Code Ocean into the journal platform will increase the impact of the AACR journals by allowing researchers to deposit their code and data essential to reproducing research results,” said Christine Battle, Publisher and Vice President, Scientific Publications at the AACR. “The mission of all AACR journals is to publish robust, hypothesis-driven science in order to further our knowledge of cancer while promoting rigor and reproducibility.”

“It is an honor to be working with the AACR, a leader in cancer research. The integration of Code Ocean into the AACR journals platform furthers our mission to make computational research easier, more collaborative, and durable. Computational biology and bioinformatics are fast becoming a critical area of importance and are a focus for Code Ocean as funders’ requirements demand more transparency.” said Simon Adar, CEO and Co-founder of Code Ocean.

The AACR will deploy Code Ocean across all nine of the AACR journals on May 21, 2020. Within the manuscript submission process via the AACR’s implementation of the EJPress online submission and peer review system authors will be invited to submit their code, creating an efficient way to associate these first-class research objects with their manuscript. Upon publication of the code, Code Ocean generates a citable Digital Object Identifier (DOI) to increase author attribution of code as part of their publication record; reviewers and other readers of the submitted manuscript will be able reproduce for themselves, using the Code Ocean online software environment, the computational analyses reported by the authors in their manuscript.

The full press release can be found here


The AACR is the largest professional organization dedicated to advancing cancer research and its mission to prevent and cure all cancers. The organization was founded in 1907, and its membership includes more than 47,000 laboratory, translational, and clinical researchers; population scientists; other healthcare professionals; and patient advocates residing in 127 countries.


Code Ocean is a cloud-based computational reproducibility platform that provides researchers in academia and biopharma with an easy way to develop, share, and run code. Code Ocean streamlines computational research with an integrated management platform so researchers can start projects (called compute capsules) faster, can collaborate easily and don't have to worry about computing resources. Once published, compute capsules are preserved for reproducibility, data provenance and reuse.

Pierre Montagano
Code Ocean
+1 215-460-8344
email us here
Visit us on social media:

Source: EIN Presswire

Dr. David Samadi: VA testing prostate cancer drug on male veterans with COVID-19

Testosterone could be a risk factor for Covid-19

men treated for advanced prostate cancer and had lower testosterone, had lower chance of getting Covid-19

relationship of testosterone and Covid-19

Covid-19 needs a protein to enter your lung system called TMPRSS2. Just like Lock and Key. Testosterone seem to be activating this protein hence more prone.

Men on hormonal treatment for advanced prostate cancer, low testosterone had four fold lower chance of getting Covid-19. Testosterone can activate the protein that the virus needs to enter our system.”

— Dr. David Samadi

NEW YORK, NEW YORK, UNITED STATES, May 28, 2020 /EINPresswire.com/ — A clinical trial to investigate the potential of treating men with COVID-19 will soon begin by the Department of Veterans Affairs (VA) to study the use of degarelix, a drug approved by the FDA for prostate cancer. The West Los Angeles VA Medical Center will lead the clinical trial but also included will be VA medical centers in Manhattan and Brooklyn in New York, and Washington State. The VA trial is expected to be completed within four months.
“I applaud the VA in their innovation to look at this medication for the possible treatment of COVID-19,” stated Dr. David Samadi, Director of Men’s Health and Urologic Oncology at St. Francis Hospital at Roslyn, New York. “The more knowledge we can collect with the hope of finding that breakthrough drug that can conquer this virus, the better for all of us.”
The VA announced that the study will include almost 200 male veterans hospitalized with COVID-19. It will be a double-blind, randomized controlled trial comparing degarelix to a placebo.
“Degarelix, also known as Firmagon, is a treatment for advanced hormone dependent prostate cancer and works by decreasing the amount of testosterone produced by the body,” explained Dr. Samadi. “The hormone testosterone can fuel the growth of prostate cancer so this medication temporarily suppresses the body’s production of this hormone with the intent of slowing or stopping the spread of prostate cancer. The researchers with this study believe that if testosterone levels are lowered temporarily, then this might prevent the virus from infiltrating lung cells.”
So far what is known about COVID-19, is the short- and long-term effects it has on lung health for some people. Lung complications can include pneumonia and in more severe cases, acute respiratory distress syndrome (ARDS), along with sepsis, a complication that can cause lasting harm to the lungs and other organs.
Research has suggested that testosterone may be triggering the production of a protein called TMPRSS2 on lung tissue. This protein is believed to be what COVID-19 uses to invade lung tissue. Veterans who receive the drug as part of the clinical trial will only be given one dose of Degarelix that lasts for 28 days.
Women veterans will not be included in this study as this medication could make things worse for them by having the opposite effect of increasing the protein the virus needs to enter the lungs and increasing the severity of COVID-19 symptoms.
Dr. Samadi commented that there can be side effects from Degarelix that the male veterans might experience. These include hot flashes, weight gain, increased sweating along with night sweats, back and joint pain, and fatigue. However, the side effects should be temporary and once the treatment is done, testosterone levels will go back to normal.
“This will be a very interesting study to see what the results will reveal,” exclaimed Dr. Samadi. “It is encouraging and exciting to learn about the numerous clinical trials being conducted throughout the world with the aim of finding an effective treatment for COVID-19. We will find one and if it’s this prostate cancer drug, that’s even better.”

Dr. David Samadi is the Director of Men’s Health and Urologic Oncology at St. Francis Hospital in Long Island. He’s a renowned and highly successful board certified Urologic Oncologist Expert and Robotic Surgeon in New York City, regarded as one of the leading prostate surgeons in the U.S., with a vast expertise in prostate cancer treatment and Robotic-Assisted Laparoscopic Prostatectomy. Visit Dr. Samadi’s websites at robotic oncology and prostate cancer 911.

Dr. David Samadi, M.D.
+1 212-365-5000
email us here

Source: EIN Presswire

Techcyte Expands its Board and Adds World-Class Advisers to its Team

Techcyte recently expanded its board and advisory team through the addition of world-class medical, corporate strategy, and laboratory diagnostics experts.

To pursue our go-to-market strategy, we can’t do it alone. Our advisers have been invaluable in focusing our efforts on the highest value markets and tests.”

— Ben Cahoon, Techcyte CEO

LINDON, UT, UNITED STATES, May 28, 2020 /EINPresswire.com/ — Techcyte recently expanded its board and advisory team through the addition of world-class medical, corporate strategy, and laboratory diagnostics experts. Techcyte is currently developing and selling its deep learning image analysis platform to human, veterinary, and air quality laboratories throughout the world.

Ben Cahoon, the new CEO of Techcyte, said, “To pursue our go-to-market strategy, we can’t do it alone. Our advisers have been invaluable in focusing our efforts on the highest value markets and tests.”

Techcyte Board
– Dr. Mohamed Salama, Hematopathologist & Chief Medical Officer, Mayo Clinic Laboratories
– Kent Gordon, Chief Financial Officer, ARUP Reference Laboratories
– Michael Aicher – President, Alveo Technologies
– Kyle Wilson – Partner, BroadOak Capital Partners
– Ralph Yarro – Founder, Chairman of the Board, Techcyte
– Michael Wolfgramm – Partner, Atua Ventures
– Ben Cahoon – CEO, Techcyte
– Rick Smith – President, Techcyte

– Dr. David Gardiner – Veterinary Pathologist
– Dr. John Haines – Retired Mycologist for New York State
– Dr. Angelica Rodriguez Baca – Cytopathologist
– Dr. Stéphane Gidenne – CEO, Ketterthill Laboratory, Luxembourg
– Richard Johnson – CEO of Air Allergen and Mold Testing

As Techcyte expands its platform to provide additional solutions, we’ll continue to look for additional world-class experts to guide and direct our efforts. If you’re interested in using or integrating with the Techcyte deep learning image analysis platform to create new algorithms or markets, please contact Ben Cahoon. ben.cahoon@techcyte.com.

About Techcyte
Headquartered in Lindon, Utah, Techcyte, Inc. was founded in 2013 and is the world leader in AI-based cellular digital diagnostics. Techcyte's use of deep machine learning to perform automated analysis of whole slide microscopy images is revolutionizing digital diagnostics in research, biopharma, environmental monitoring, and human and animal health. Visit www.techcyte.com for more information.

Techcyte Media Contact:
Matt Yarro, 801-980-0414, matt.yarro@techcyte.com

Matt Yarro
Techcyte, Inc.
+1 801-980-0414
email us here
Visit us on social media:

Source: EIN Presswire

Pasqua South Medical Aesthetics Announces a Change of Locations

Regina’s premier provider of medical aesthetics has moved to a new clinic

Regina’s premier provider of medical aesthetics has moved to a new clinic

Regina’s premier provider of medical aesthetics has moved to a new clinic

REGINA, SK, CANADA, May 28, 2020 /EINPresswire.com/ — Pasqua South Medical Aesthetics has announced they have moved locations. In their new location, they look forward to continuing to provide safe and effective medical aesthetics services and treatment to their clients.

The clinic’s new location is 3275 Quance St, Regina, SK, S4V 3B7. They can still be reached by the same number (306) 559-1310 to book appointments or make inquiries about their services.

Clinic owner, Dr. Tomi Mitchell, has put together an experienced and multi-disciplinary team committed to helping the people of Regina look and feel their very best. Pasqua South Medical Aesthetics offers a variety of services, including body shaping, facial fillers, BOTOX® Cosmetic, laser hair removal, medical-grade skincare, and much more.

They can be contacted via phone or email for appointments and their website offers plenty of useful information: http://pasquasouthmedicalaesthetics.com/

Dr. Tomi Mitchell
Pasqua South Medical Aesthetics
+1 306-559-1310
email us here
Visit us on social media:

Source: EIN Presswire

Rothman Orthopaedic Institute Partners with Radix Health to Launch Self-Scheduling for Telehealth

Rothman Orthopaedic Institute Partners with Radix Health

Rothman Orthopaedic Institute Partners with Radix Health

Partnership Enables Rothman to Further Enhance Patient Experience and Patient Access in the New Normal

The current health pandemic created an unprecedented demand for virtual visits, and we knew that we needed to quickly adopt online scheduling to meet the growing demand.”

— Alexander R. Vaccaro, MD, PhD, MBA

ATLANTA, GA, UNITED STATES, May 28, 2020 /EINPresswire.com/ — Radix Health, Inc., a leading provider of patient access technologies, today announced that it has partnered with Rothman Orthopaedic Institute, a world leader in the field of orthopaedics with offices in Greater Philadelphia, New Jersey and New York. Health systems and medical groups have undergone a seismic shift due to the COVID-19 pandemic, and Radix Health’s DASH software will help Rothman Orthopaedics meet the unprecedented demand for telehealth services and deliver a seamless virtual visit experience in the New Normal.

Delivering a Seamless Patient Experience in the New Normal

Radix’s DASH software will help Rothman Orthopaedics adapt to the growing need for on-demand and scheduled virtual visits. The DASH platform enables frictionless access to care by giving patients the ability to search providers and identify the right doctor to meet their medical needs at the right time. Patients are able to self-schedule telehealth visits across a number of digital channels.

Words from the President of Rothman Orthopaedic Institute and the CEO of Radix Health

“As leaders in orthopaedic care, it’s our responsibility to ensure our patients have access to the right care at the right time,” said Alexander R. Vaccaro, MD, PhD, MBA, President of Rothman Orthopaedic Institute, Richard H. Rothman Professor and Chairman of the Department of Orthopaedics, and Professor of Neurosurgery at Thomas Jefferson University and Hospitals. “The current health pandemic created an unprecedented demand for virtual visits, and we knew that we needed to quickly adopt online scheduling to meet the growing demand. We are excited about our ability to streamline access to virtual care and offer online scheduling through various digital channels.”

“Rothman Orthopaedics is a national leader in orthopaedic care.” said Arun Mohan, MD, MBA, CEO and Co-Founder of Radix Health. “A key component of telehealth is providing patients with the ability to identify the right doctor for their needs and to ensure the condition can be evaluated via telemedicine. We’re improving patient access to virtual visits during a time when many patients are relying on telehealth for much needed care.”

About Rothman Orthopaedic Institute

Rothman Orthopaedic Institute is a world-leader in the field of orthopaedics providing communities in Pennsylvania, New Jersey and New York with high-quality, compassionate and affordable musculoskeletal care that is grounded in evidence-based medicine—the results of which will exceed expectations.

Rothman Orthopaedic Institute orthopaedists treat patients at nearly 40 office locations, two of which include orthopaedic urgent care clinics. Rothman also has surgical privileges at 58 facilities across the tri-state region. With experts in nine orthopaedic sub-specialties including spine, hip and knee, foot and ankle, shoulder and elbow, hand and wrist, sports medicine, physical medicine and rehabilitation, orthopaedic oncology and trauma, Rothman Orthopaedic Institute is recognized for excellence in clinical treatment methods, research, education and technology.

Consistently recognized as national and regional “Top Docs,” Rothman Orthopaedic Institute is proud to be the official team physicians for the Philadelphia Eagles, Phillies, 76ers, the iconic Radio City Rockettes, The Big East Conference, as well as over 40 college and high school teams.

For more information about Rothman Orthopaedic Institute please call 1-800-321-9999 or visit www.RothmanOrtho.com.

About Radix Health

Radix Health is a technology company that believes patient experience starts with patient access. Our data-driven solutions align provider supply with patient demand, maximizing existing capacity and reducing delays in care. We help leading medical groups optimize every step of a patient’s appointment journey – from alerting patients to needed care, helping them find the right provider, scheduling an appointment across multiple channels, and engaging with patients until the day of their visit. We take the busy work out of getting patients in the door so you can focus on the hard work of keeping them healthy. To learn more, please visit www.radixhealth.com or connect with us on LinkedIn, Facebook, or Twitter.

Ellen Sirull
Radix Health
+1 404-590-0579
email us here
Visit us on social media:

Source: EIN Presswire